CMA investigates Vifor Pharma for suspected of restriction of competition in iron deficiency treatment market

The UK Consumer & Market’s Authority (CMA) has launched an investigation against Vifor Pharma (Vifor) for allegations of engaging in an anti-competitive conduct in the market for supply of intravenous (IV) iron deficiency treatments. According to CMA, in order to promote its IV iron deficiency offering – Ferinject, Vifor has been restricting competition by making misleading claims to the healthcare professionals regarding the lack of safety & effectives of a rival high-dose IV iron deficiency treatment – Monofer, supplied by the company Pharmacosmos.